Kempharm Inc

(NASDAQ: KMPH)
Ajouter à Portefeuille
+0,02 (+5,00%)
en date du jan 17, 2020

Profil
Symbole KMPH
Marché NASDAQ
Informations de contact
1180 Celebration Boulevard Suite 103
Celebration, FL USA
P: 321-939-3416
Président Travis C. Mickle
Bénéfices à vue d'oeuil
Bénéfices 09/30/19
0.09
06/30/19
-0.33
03/31/19
-0.46
12/31/18
0.21
Ratio prix/bénéfices N/A
Croissance du BPA 82,97
Most Recent Earnings ($) 0,06
Annual EPS ($) -0,93
Résumé business
KemPharm Inc. is a specialty pharmaceutical company which is engaged in the discovery and development of new molecular entity prodrugs. Its product candidates include KP201/APAP KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder and KP303 for the treatment of central nervous system disorders which are in preclinical trail stage. The Company through its LAT platform technology generate prodrug. KemPharm Inc. is based in CORALVILLE United States.
Industrie/Secteur Information not available.